Lyle G Best

Dr. Lyle G Best

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2005 in Circulation
Verified
Journal Article
Closed access
PDF file
Lyle G BestLyle G Best
Lyle G Best
YZYing Zhang
Ying Zhang
ELElisa T. Lee
Elisa T. Lee
JYJeun-Liang Yeh
Jeun-Liang Yeh
LCLinda Cowan
Linda Cowan
BHBarbara V. Howard
Barbara V. Howard
Background— High-sensitivity C-reactive protein (CRP) has been investigated extensively as a marker for predicting the risk of cardiovascular disease (CVD). CVD accounts for a large proportion of mortality and morbidity in American Indians; we sought to test the association of CRP and CVD in a population-based American Indian cohort 45 to 74 years old. Methods and Results— Of 3277 participants who were CVD-free at baseline, 542 had CRP >10 mg/L and were excluded from analysis; 50.1% of those included had diabetes. There were 343 CVD events among this cohort during a median follow-up of 6.2 years. Multiple CVD risk factors were used as covariates in Cox proportional-hazard models. After exclusions, the median CRP (3.2 mg/L) was higher than reported in many other populations. CRP predicted CVD in models adjusted for traditional risk factors, but not when albuminuria and fibrinogen were included. In subgroup analysis, CRP was strongly related to incident CVD among nondiabetic women participants, even after adjustment for traditional CVD risk factors and other indicators of inflammation. Conversely, CRP was elevated beyond the useful range of the American Heart Association/Centers for Disease Control and Prevention clinical guidelines in 16% of this population, and CRP was not predictive of CVD in important subgroups, such as those with diabetes. Conclusions— CRP was a predictor of CVD in this American Indian population with a high prevalence of diabetes and other risk factors. The predictive ability of CRP varies considerably among subgroups with different risk factor profiles.

3 February 2004 in Circulation
Verified
Journal Article
Closed access
Lyle G BestLyle G Best
Lyle G Best
MDMichael Davidson
Michael Davidson
KNKari E. North
Kari E. North
JMJean W. MacCluer
Jean W. MacCluer
YZYing Zhang
Ying Zhang
RFRobert E. Ferrell
Robert E. Ferrell
Background— Mannose-binding lectin (MBL) is a circulating immune factor responsible for opsonization of pathogens and directly activating complement. Common variations in the MBL gene are responsible for an opsonic deficiency that affects 5% to 7% of whites and are associated with increased susceptibility to infections. After a preliminary report associating these variations with coronary artery disease (CAD), we determined MBL genotypes in 3 American Indian communities experiencing an increased mortality and morbidity from CAD. Methods and Results— We examined DNA from 434 participants in a population-based cohort, the Strong Heart Study. Genotypes for 3 common MBL coding variations and 1 promoter polymorphism were determined. The frequency of a composite genotype that conferred low MBL levels was 20.7% in 217 cases and 11.1% in matched controls without CAD. A conditional logistic regression model indicated a univariate OR for CAD of 2.3 (95% CI 1.3 to 4.2, P =0.005) for the variant genotypes. After adjustment for demographic and CAD risk factors, including type 2 diabetes mellitus, fibrinogen, triglycerides, and hypertension, the OR was 3.2 (95% CI 1.5 to 7.0, P =0.004). Conclusions— Variant MBL genotypes coding for markedly diminished levels of MBL are predictive of CAD. After adjustment for multiple traditional risk factors for ischemic heart disease, this association remains significant. A high prevalence of variant MBL alleles and CAD in this population suggests that potentially important public health benefits may accrue from future interventions based on these genotypes.

30 April 2019 in Cardiovascular Diabetology
Verified
Journal Article
Open access
PDF file
Costantino MancusiCostantino Mancusi
Costantino Mancusi
GSGiovanni de Simone
Giovanni de Simone
Lyle G BestLyle G Best
Lyle G Best
WWWenyu Wang
Wenyu Wang
YZYing Zhang
Ying Zhang
RDRichard Devereux
Richard Devereux
Background: Myocardial energetic efficiency (MEE), is a strong predictor of CV events in hypertensive patient and is reduced in patients with diabetes and metabolic syndrome. We hypothesized that severity of insulin resistance (by HOMA-IR) negatively influences MEE in participants from the Strong Heart Study (SHS). Methods: We selected non-diabetic participants (n = 3128, 47 ± 17 years, 1807 women, 1447 obese, 870 hypertensive) free of cardiovascular (CV) disease, by merging two cohorts (Strong Heart Study and Strong Heart Family Study, age range 18–93). MEE was estimated as stroke work (SW = systolic blood pressure [SBP] × stroke volume [SV])/“double product” of SBP × heart rate (HR), as an estimate of O2 consumption, which can be simplified as SV/HR ratio and expressed in ml/sec. Due to the strong correlation, MEE was normalized by left ventricular (LV) mass (MEEi). Results: Linear trend analyses showed that with increasing quartiles of HOMA-IR patients were older, more likely to be women, obese and hypertensive, with a trend toward a worse lipid profile (all p for trend < 0.001), progressive increase in LV mass index, stroke index and cardiac index and decline of wall mechanics (all p < 0.0001). In multivariable regression, after adjusting for confounders, and including a kinship coefficient to correct for relatedness, MEEi was negatively associated with HOMA-IR, independently of significant associations with age, sex, blood pressure, lipid profile and central obesity (all p < 0.0001). Conclusions: Severity of insulin resistance has significant and independent negative impact on myocardial mechano-energetic efficiency in nondiabetic individual from a population study of American Indians. Trial registration number NCT00005134, Name of registry: Strong Heart Study, URL of registry: https://clinicaltrials.gov/ct2/show/NCT00005134, Date of registration: May 25, 2000, Date of enrolment of the first participant to the trial: September 1988

1 May 2016 in Environmental Research
Verified
Journal Article
Closed access
YPYuanjie Pang
Yuanjie Pang
RPRoger D. Peng
Roger D. Peng
MJMiranda R. Jones
Miranda R. Jones
KFKevin A. Francesconi
Kevin A. Francesconi
WGWalter Goessler
Walter Goessler
ANAna Navas-Acien
Ana Navas-Acien

1 July 2017 in Food and Chemical Toxicology
Verified
Journal Article
Closed access
MSMiranda Jones Spratlen
Miranda Jones Spratlen
MGMary V Gamble
Mary V Gamble
MGMaria Grau-Perez
Maria Grau-Perez
CKChin-Chi Kuo
Chin-Chi Kuo
Lyle G BestLyle G Best
Lyle G Best
ANAna Navas-Acien
Ana Navas-Acien

1 January 2019 in Environmental Research
Verified
Journal Article
Closed access
MPMartha Powers
Martha Powers
JYJoseph Yracheta
Joseph Yracheta
DHDavid Harvey
David Harvey
MOMarcia O’leary
Marcia O’leary
Lyle G BestLyle G Best
Lyle G Best
CGChristine Marie George
Christine Marie George